Nanomolar Benzothiazole-Based Inhibitors of 17β-HSD10 with Cellular Bioactivity

Area of Science:

• Biochemistry
• Neuroscience
• Medicinal Chemistry

Background:

• 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) is a multifunctional mitochondrial enzyme implicated in Alzheimer's disease (AD).
• Overexpression of 17β-HSD10 and its interaction with amyloid-β contribute to mitochondrial dysfunction and neuronal stress in AD.
• 17β-HSD10 represents a potential therapeutic target for AD and other pathologies.

Purpose of the Study:

• To design and synthesize novel benzothiazole-derived inhibitors targeting 17β-HSD10.
• To evaluate the inhibitory potency, enzyme interaction, and cytotoxicity of these new compounds.
• To identify potent and safe drug candidates for potential therapeutic applications.

Main Methods:

• Structure-activity relationship (SAR) analysis of previously published inhibitors.
• Enzyme-based assays to determine inhibitory potency (IC50 values).
• Cell-based assays to assess target engagement and cytotoxicity.

Main Results:

• Several novel benzothiazole derivatives demonstrated significantly higher inhibitory potential against 17β-HSD10 compared to existing benzothiazolyl ureas.
• The most effective compounds exhibited mixed-type inhibition with nanomolar IC50 values against the purified enzyme.
• Compounds also showed good target engagement in cellular assays with low cytotoxicity, with some achieving low micromolar IC50 values.

Conclusions:

• The newly designed benzothiazole derivatives are potent inhibitors of 17β-HSD10.
• These compounds show promise as therapeutic agents for conditions involving 17β-HSD10, particularly Alzheimer's disease.
• Further development of these inhibitors could lead to novel treatments with improved efficacy and safety profiles.